Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GOT1 | P17174 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730835 | 0.83 | ALDH1A1 (0.47) | NNMTGAAMAPTALDH1A1GOT1 | |
| SCHEMBL3174330 | 0.82 | NNMT (0.67) | NNMTMAPTALDH1A1GSK3BKMT2A | |
| SCHEMBL12471478 | 0.79 | NNMT (0.46) | NNMTGAAMAPTALDH1A1GOT1 | |
| SCHEMBL7667785 | 0.77 | NNMT (0.49) | NNMTGAAMAPTALDH1A1GSK3B | |
| Hydrochloric Acid SCHEMBL26094699 | 0.77 | NNMT (0.44) | NNMTGAAMAPTALDH1A1KDM4E | |
| SCHEMBL31211632 | 0.76 | NNMT (0.47) | NNMTALDH1A1GSK3BKMT2AKDM4E | |
| SCHEMBL29128681 | 0.75 | NNMT (0.42) | NNMTALDH1A1GSK3BKMT2AKDM4E | |
| SCHEMBL4889620 | 0.74 | HCAR3 (0.46) | NNMTALDH1A1PIM1KDM4ESMN1; SMN2 | |
| SCHEMBL29686885 | 0.74 | NNMT (0.42) | NNMTMAPTGSK3BKDM4EHTT | |
| SCHEMBL25231402 | 0.73 | ALDH1A1 (0.38) | NNMTGAAMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1026 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| US-12396982-B2 | Compositions of matter and pharmaceutical compositions | ATAI THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20250090536-A1 | USES | INTRA-CELLULAR THERAPIES, INC. | 2025-03-20 | — | — | US | claimed |
| US-20250041273-A1 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | ATAI LIFE SCIENCES N.V. (DE) | 2025-02-06 | — | — | US | claimed |
| US-12194042-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-01-14 | — | — | US | claimed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| US-20240350455-A1 | COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS | CAAMTECH, INC. (US) | 2024-10-24 | — | — | US | claimed |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | Intrabio Ltd. (GB) | 2024-10-22 | — | — | US | claimed |
| US-12053453-B2 | Compositions of matter and pharmaceutical compositions | PSILERA INC. (US) | 2024-08-06 | — | — | US | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | CNR2, CNR1, OPRM1 | NNMT 241/4885GAA 1077/4885MAPT 792/4885 |
| US-12194042-B2 | Uses | NLN, SLC6A3, SLC18A2 | NNMT 407/4885GAA 223/4885MAPT 797/4885 |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | NNMT 148/4885GAA 1770/4885MAPT 653/4885 |
| US-20240350455-A1 | COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS | HTR1A, HTR2A, HTR1B | NNMT 1917/4885GAA 2108/4885MAPT 1761/4885 |
| US-20250041273-A1 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | TPH1, HTR2C, HTR1B | NNMT 746/4885GAA 3877/4885MAPT 33/4885 |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | HNMT, MAOA, MAOB | NNMT 206/4885GAA 252/4885MAPT 1996/4885 |
| US-12053453-B2 | Compositions of matter and pharmaceutical compositions | TPH1, HTR1B, HTR2C | NNMT 585/4885GAA 3544/4885MAPT 24/4885 |
| US-20250090536-A1 | USES | NLN, SLC6A3, SLC18A2 | NNMT 407/4885GAA 223/4885MAPT 797/4885 |
| US-12396982-B2 | Compositions of matter and pharmaceutical compositions | TPH1, HTR1B, HTR2C | NNMT 585/4885GAA 3544/4885MAPT 24/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | NNMT 119/4885GAA 64/4885MAPT 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.